# Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

> **NCT07018050** · PHASE2 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 160 (estimated)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **DRUG:** QLS32015
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone
- **DRUG:** QL2109 or Daratumumab
- **DRUG:** Bortezomib
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT07018050
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-12
- **Primary completion:** 2027-11
- **Final completion:** 2028-07
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07018050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07018050, "Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07018050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*